ADC Therapeutics SA Return on Tangible Equity 2019-2022 | ADCT

Current and historical return on tangible equity values for ADC Therapeutics SA (ADCT) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
ADC Therapeutics SA Return On Tangible Equity Historical Data
Date TTM Net Income Tangible Equity Return on Tangible Equity
2022-12-31 $-0.16B $0.07B -150.72%
2022-09-30 $-0.17B $0.09B -134.69%
2022-06-30 $-0.19B $0.10B -129.64%
2022-03-31 $-0.20B $0.15B -110.73%
2021-12-31 $-0.23B $0.15B -109.09%
2021-09-30 $-0.25B $0.17B -99.31%
2021-06-30 $-0.20B $0.23B -66.39%
2021-03-31 $-0.26B $0.29B -87.48%
2020-12-31 $-0.25B $0.33B -112.07%
2020-06-30 $-0.20B $0.19B -429.95%
2020-03-31 $-0.10B inf%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.152B $0.210B
ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA is based in LAUSANNE, Switzerland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $140.576B 8.70
GSK (GSK) United Kingdom $75.923B 9.52
Bio-Rad Laboratories (BIO.B) United States $13.735B 32.61
QIAGEN (QGEN) Netherlands $10.436B 19.34
Ginkgo Bioworks Holdings (DNA) United States $2.549B 0.00
Arcus Biosciences (RCUS) United States $1.194B 0.00
Biohaven (BHVN) United States $0.913B 0.00
Emergent Biosolutions (EBS) United States $0.394B 0.00
Enzo Biochem (ENZ) United States $0.106B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.012B 0.00